Essential Thrombocythemia clinical trials at UCLA
2 in progress, 0 open to eligible people
CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Sorry, in progress, not accepting new patients
Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Los Angeles, California and other locations
Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Sorry, in progress, not accepting new patients
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Los Angeles, California and other locations
Our lead scientists for Essential Thrombocythemia research studies include Gary Schiller.
Last updated: